Holen Sie sich die Stockscreener-App
9.27
3.93%
0.37
Schlusskurs vom Vortag:
$8.90
Offen:
$8.88
24-Stunden-Volumen:
499.57K
Relative Volume:
0.47
Marktkapitalisierung:
$506.88M
Einnahmen:
$27.46M
Nettoeinkommen (Verlust:
$-46.05M
KGV:
-7.186
EPS:
-1.29
Netto-Cashflow:
$-33.83M
1W Leistung:
-23.04%
1M Leistung:
-27.68%
6M Leistung:
+14.62%
1J Leistung:
+29.73%
1-Tages-Spanne:
$8.82
$9.36
1-Wochen-Bereich:
$8.6133
$12.23
52-Wochen-Spanne:
$6.19
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Firmenname
Zevra Therapeutics Inc
Sektor
Branche
Telefon
(321) 939-3416
Adresse
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Vergleichen Sie ZVRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
9.27 | 515.63M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.98 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.62 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.00 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
648.95 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-08 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-10-07 | Eingeleitet | Guggenheim | Buy |
| 2024-09-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-24 | Bestätigt | Maxim Group | Buy |
| 2024-04-02 | Bestätigt | Maxim Group | Buy |
| 2024-03-12 | Eingeleitet | William Blair | Outperform |
| 2023-03-17 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
Zevra signals continued MIPLYFFA momentum with 26% revenue growth and $150M PRV sale strengthening balance sheet - MSN
Zevra Therapeutics’ Earnings Call: Optimism Amid Challenges - MSN
Zevra Therapeutics’ SWOT analysis: stock soars on MIPLYFFA success, pipeline potential - Investing.com
Zevra Therapeutics Faces $58.7 Million Impairment Charge, Raising Concerns Over Financial Stability - TipRanks
Zevra Therapeutics at Canaccord Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
JMP Securities maintains Market Outperform on Zevra, lowers PT to $18. - AInvest
Price Channel Expanding on Zevra Therapeutics Inc.’s ChartDividend Hike & Safe Entry Point Alerts - sundaytimes.kr
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2025 Earnings Call Transcript - Insider Monkey
Zevra Therapeutics price target lowered to $18 from $19 at Citizens JMP - TipRanks
Zevra Therapeutics shares fall 9.01% premarket despite Q2 profit and revenue growth. - AInvest
Zevra Therapeutics stock price target lowered to $18 at Citizens JMP - Investing.com
Zevra Therapeutics shares fall 10.54% premarket despite Q2 revenue beating estimates. - AInvest
Zevra Therapeutics Inc (ZVRA) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Zevra Revenue Jumps 486 Percent in Q2 - AOL.com
Zevra Therapeutics Inc (ZVRA) Q2 2025 Earnings Call Highlights: - GuruFocus
Zevra Reports Second Quarter 2025 Financial Results and Corporate Update - GlobeNewswire
Zevra Therapeutics Reports Strong Q2 2025 Results - TipRanks
Zevra Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Zevra Therapeutics' Q2 2025 Earnings Call: Unraveling Contradictions in Patient Enrollment Strategies and Reimbursement Timelines - AInvest
Zevra Therapeutics (ZVRA) Reports Strong Q2 2025 Financials - GuruFocus
Transcript : Zevra Therapeutics, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Zevra Therapeutics Outpaces Earnings Estimates And Investor Optimism Builds - Finimize
Zevra Therapeutics: Q2 Earnings Snapshot - CT Insider
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings call transcript: Zevra Therapeutics Q2 2025 misses EPS, revenue shines - Investing.com
ZEVRA THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Zevra Q2 2025 net revenue at $25.9mln, arimoclomol approval sought in EU - AInvest
Zevra Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Zevra Therapeutics reports Q2 EPS $1.21, consensus $1.38 - TipRanks
Zevra Therapeutics Q2 Swing to Profits, Revenue Rises - MarketScreener
Zevra Therapeutics earnings missed by $2.25, revenue topped estimates - Investing.com Canada
Zevra Therapeutics falls as significant earnings miss overshadows revenue beat - Investing.com Nigeria
Zevra Therapeutics' Q2 Earnings Outperformance and Strategic Momentum in Rare Disease Therapies: A Deep Dive into Long-Term Investment Viability - AInvest
Zevra Therapeutics Q2 revenue beats estimates - MarketScreener
Zevra Therapeutics Q2 Non-GAAP EPS Misses by $1.44, Revenue Surpasses Expectations - AInvest
Zevra Therapeutics Inc options imply 12.4% move in share price post-earnings - TipRanks
Those who invested in Zevra Therapeutics (NASDAQ:ZVRA) three years ago are up 102% - Yahoo Finance
Zevra Therapeutics Inc (ZVRA) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates - Nasdaq
Zevra Therapeutics Inc. Bounces Off Moving Average SupportLong Hold Safe Return Strategy Reviewed - beatles.ru
Does Zvra plan to issue more stock? - AInvest
Zevra ZVRA 2025Q2 Earnings Preview Potential Upside on Data-Driven Regulatory Strategy - AInvest
Zevra Therapeutics Inc expected to post earnings of $1.50 a shareEarnings Preview - TradingView
What Makes Zevra Therapeutics (ZVRA) a Good Fit for 'Trend Investing' - Yahoo Finance
Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference | ZVRA Stock News - GuruFocus
Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference - The Manila Times
Rare Disease Innovator Zevra Therapeutics Sets Key Investor Presentation at Major Growth Conference - Stock Titan
Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth - sharewise.com
Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call - 富途牛牛
Zevra Therapeutics to report Q2 2025 results on Aug 12. - AInvest
Quant Funds Rotate Into Zevra Therapeutics Inc. StockStock Screener With Smart Filters Highlights Top Picks - metal.it
Finanzdaten der Zevra Therapeutics Inc-Aktie (ZVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.37%
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):